Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Keiko Tanaka-Amino"'
Publikováno v:
Am J Nephrol
Introduction: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for treating anemia of chronic kidney disease (CKD). This post hoc analysis of a Japanese, open-label, partially randomized, phase 3 study in nondialysis-depend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::797dc94288379336b25d27f491306f2b
https://europepmc.org/articles/PMC8686708/
https://europepmc.org/articles/PMC8686708/
Autor:
Masakazu Terauchi, Matthias Stoelzel, Keiko Tanaka-Amino, Yukiko Nishita, Hiroshi Shimokata, Makiko Tomida, Tomomi Kimura, Rei Otsuka, Chikako Tange
Publikováno v:
The journal of obstetrics and gynaecology research. 47(10)
Aim To assess prevalence and characteristics of vasomotor symptoms in community-dwelling Japanese women. Methods These were cross-sectional analyses using data from the National Institute for Longevity Sciences-Longitudinal Study of Aging. The main o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::993f4b3492f6b9e839a8cd860f38e830
https://pubmed.ncbi.nlm.nih.gov/34278662
https://pubmed.ncbi.nlm.nih.gov/34278662
Publikováno v:
European journal of pharmacology. 905
The majority of women experience vasomotor symptoms (VMS), such as hot flashes and night sweats, during the menopausal transition. Recent evidence strongly suggests a connection between neurokinin 3 (NK3) receptor signaling and VMS associated with me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3376a054c69519dd20501aef2922aa8c
https://pubmed.ncbi.nlm.nih.gov/34048742
https://pubmed.ncbi.nlm.nih.gov/34048742
Autor:
Masaki Abe, Keiko Tanaka-Amino, Hikaru Mitori, Megumi Eguchi, Yutaka Inoki, Yusuke Wada, Akira Imasato, Mitsuhiro Kondo, Hiroshi Kajiyama, Toshihide Mimura, Hiroshi Moritani, Yuichi Tomura
Publikováno v:
Experimental Biology and Medicine. 241:1865-1876
Urinary nephrin is a potential non-invasive biomarker of disease. To date, however, most studies of urinary nephrin have been conducted in animal models of diabetic nephropathy, and correlations between urinary nephrin-to-creatinine ratio and other p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afcb4e9f45558fa83dcfa524c619221b
https://doi.org/10.1177/1535370216651937
https://doi.org/10.1177/1535370216651937
Publikováno v:
Acta Diabetologica. 47:43-48
ASP4000 ((2S)-1-{[(1R,3S,4S,6R)-6-hydroxy-2-azabicyclo[2.2.1]hept-3-yl]carbonyl}-2-pyrrolidinecarbonitrile hydrochloride) is a novel, potent and selective dipeptidyl peptidase 4 (DPP IV, EC 3.4.14.5) inhibitor (Keiko Tanaka-Amino et al. in Eur J phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f93fc3f234886f3ff2296bc2eeca49a
https://doi.org/10.1007/s00592-009-0096-5
https://doi.org/10.1007/s00592-009-0096-5
Autor:
Ichiro Shima, Keiko Tanaka-Amino, Seitaro Muto, Shoji Takakura, Kazumi Matsumoto, Yoshifumi Hatakeyama
Publikováno v:
European Journal of Pharmacology. 590:444-449
ASP4000, (2S)-1-{[(1R,3S,4S,6R)-6-hydroxy-2-azabicyclo[2.2.1]hept-3-yl]carbonyl}-2-pyrrolidinecar bonitrile hydrochloride, is a novel dipeptidyl peptidase (DPP) 4 inhibitor. In the present study, we characterized the compound as an oral antidiabetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b272eeab2fcb290ae68fb3ea5c62383
https://doi.org/10.1016/j.ejphar.2008.05.034
https://doi.org/10.1016/j.ejphar.2008.05.034
Publikováno v:
Pharmacological research. 60(4)
Glucagon-like peptide-1 (GLP-1), an incretin hormone, is essential for the regulation of insulin secretion and glucose homeostasis. GLP-1 is rapidly degraded by dipeptidyl peptidase 4 (DPP4); therefore, DPP4 inhibitors are considered to be a novel cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb29a3c8e45bf7ccdec92708e718f876
https://pubmed.ncbi.nlm.nih.gov/19520592
https://pubmed.ncbi.nlm.nih.gov/19520592